Bausch + LombBLCO
Market Cap: $5.6B
About: Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Employees: 13,300
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
5% more funds holding
Funds holding: 85 [Q1] → 89 (+4) [Q2]
0.86% more ownership
Funds ownership: 10.73% [Q1] → 11.59% (+0.86%) [Q2]
9% less capital invested
Capital invested by funds: $651M [Q1] → $591M (-$60.1M) [Q2]
50% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $2.57M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
RBC Capital Douglas Miehm 71% 1-year accuracy 5 / 7 met price target | 26%upside $20 | Outperform Reiterated | 5 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 19%upside $19 | Buy Maintained | 5 Aug 2024 |
Deutsche Bank Pito Chickering 82% 1-year accuracy 9 / 11 met price target | 13%upside $18 | Hold Maintained | 1 Aug 2024 |
RBC Capital Douglas Miehm 71% 1-year accuracy 5 / 7 met price target | 26%upside $20 | Outperform Reiterated | 1 Aug 2024 |
Raymond James Gary Nachman 58% 1-year accuracy 7 / 12 met price target | 19%upside $19 | Outperform Initiated | 10 Jul 2024 |